Stem Cell Clinic

Placental Stem Cell Collection and Storage Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and Forecast to 2025 – Apsters…

By adminJuly 14, 2020Stell Cell Research

A detailed research on Placental Stem Cell Collection and Storage market recently added by Market Study Report, LLC, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industrys size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in the projection timeline, while including their expansion strategies and portfolio.

Request a sample Report of Placental Stem Cell Collection and Storage Market at:https://www.marketstudyreport.com/request-a-sample/2713619?utm_source=apsters.com&utm_medium=Ram

Forecast to be a highly lucrative business vertical, the Placental Stem Cell Collection and Storage market has been projected to accumulate modest proceeds by the end of the projected timeframe. Incorporating a concise analysis of the Placental Stem Cell Collection and Storage market in meticulous detail, the Placental Stem Cell Collection and Storage market research study aims to deliver valuable insights with reference to factors such as market size, revenue forecast, sales volume, and others. The segmentation of the Placental Stem Cell Collection and Storage market as well as the driving forces impacting the industry landscape are categorically provided in the report.

What does the Placental Stem Cell Collection and Storage market report incorporate in terms of the regional terrain of the industry?

What does the Placental Stem Cell Collection and Storage market report include as far as the competitive landscape of the industry is considered?

What are some of the pivotal pointers encompassed in the Placental Stem Cell Collection and Storage market report?

, as per the report.

Ask for Discount on Placental Stem Cell Collection and Storage Market Report at:https://www.marketstudyreport.com/check-for-discount/2713619?utm_source=apsters.com&utm_medium=Ram

The research study in Placental Stem Cell Collection and Storage market is essentially a detailed evaluation of this business space, that is touted to register a commendable annual growth rate over the forecast period. The report is also inclusive of significant information with respect to the Placental Stem Cell Collection and Storage market dynamics as in, the driving factors influencing the commercialization landscape of this business, myriad opportunities prevalent in this industry, and the various risks that this market is characterized by.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-placental-stem-cell-collection-and-storage-market-2020-by-company-regions-type-and-application-forecast-to-2025

Related Reports:

1. Global Acid Resistant Capsules Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-acid-resistant-capsules-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Organic Capsules Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Read More: https://www.marketstudyreport.com/reports/global-organic-capsules-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the original post:
Placental Stem Cell Collection and Storage Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and Forecast to 2025 - Apsters...

Cell Separation Technology Market Potential Growth, Share, Demand And Analysis of Key Players- Research Forecasts To 2027 – 3rd Watch News

By adminJuly 14, 2020Stell Cell Research

Cell Separation Technology Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 2027

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1925

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request for Analysis of COVID19 Impact on Cell Separation Technology Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Buy Cell Separation Technology Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=1925&ltype=S

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billionby 2100.

Global Cell Separation Technology Market: Segmentation

Cell Separation Technology Market by Technology

Cell Separation Technology Market by Application

Cell Separation Technology Market by End User

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website:https://www.transparencymarketresearch.com/

Link:
Cell Separation Technology Market Potential Growth, Share, Demand And Analysis of Key Players- Research Forecasts To 2027 - 3rd Watch News

Breakthrough Science: Scientists Discover New Method To Solve Male Infertility – International Business Times

By adminJuly 14, 2020Stem Cell Clinic

KEY POINTS

More than a hundred million men across the world suffer from infertility. Scientists have discovered the answer to treating infertility may be in spermatogonial stem cells (SSC) that are required for generating sperms.

SSCs in the testes can be transferred to test tubes which will then be cultured and nudged until it becomes a fully-fledged sperm. However, identifying the perfect conditions to grow these sperm stem cells in a lab has been a challenge. The experts at the University of California San Diego School of Medicine have now developed a reliable way of doing this.

These specialized cells, which have the potential to help men father children even at the age of 65, continually self-renew themselves to generate more and develop into sperms so prolifically that men and even transgender or gender-fluid individuals produce more than a thousand new sperms every few seconds.

We think our approach -- which is backed up by several techniques, including single-cell RNA-sequencing analysis -- is a significant step toward bringing SSC therapy into the clinic," News Medical quoted Miles Wilkinson, Ph.D., the studys senior author and distinguished Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of California San Diego.

The challenge lied in being able to distinguish SSCs from other cells in the testes. But the experts at the University of California San Diego identified a new technique called single-cell RNA sequencing to define the likely molecular characteristics that are specific to the sperm stem cells.

The researchers used their new method to purify the human SSCs and gathered the profile of genes expressed in these cells to make guesses as to the conditions that might best support their growth in laboratory conditions.

After using over 30 human testis biopsies, they were able to determine just the ideal conditions required to culture immature germ cells that have the characteristics of sperm stem cells.

One conditionAKT pathway inhibitionhad the unique ability to selectively support the culture of primitive human undifferentiated spermatogonia (uSPG). This raises the possibility that supplementation with an AKT inhibitor could be used to culture human SSCs in vitro for therapeutic applications, concluded the researchers in their paper published in the journal PNAS.

new study reveals egg cells are very choosy when it comes to the sperm that will fertilize it Photo: TBIT - Pixabay

Visit link:
Breakthrough Science: Scientists Discover New Method To Solve Male Infertility - International Business Times

Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies -…

By adminJuly 14, 2020Stem Cell Treatment

July 14, 2020 08:00 ET | Source: Fate Therapeutics, Inc.

License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients

Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor Eradication

SAN DIEGO, July 14, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class approach that renders off-the-shelf allogeneic cell products resistant to host immune rejection. Preclinical studies published in the journal Nature Biotechnology (https://www.nature.com/articles/s41587-020-0601-5) demonstrate that allogeneic cells engineered with a novel alloimmune defense receptor (ADR) are protected from both T- and NK-cell mediated rejection, and provide proof-of-concept that ADR-expressing allogeneic cell therapies can durably persist in immunocompetent recipients.

Allogeneic cell therapy requires a patient to endure systemic lympho-conditioning to suppress the immune system and mitigate cellular rejection, often resulting in severe blood cell deficiencies and related toxicities. There is great interest in strategies that enable allogeneic cells to overcome host immunity and evade immune rejection while maintaining a patients functional hematopoietic system, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. The published preclinical data provide compelling evidence that allogeneic cell therapies armed with novel alloimmune defense receptors can effectively abrogate both T- and NK-cell rejection responses and can persist and remain functional in immunocompetent patients.

ADRs are synthetic receptors that selectively recognize cell surface receptors, such as 4-1BB, that are uniquely expressed on activated lymphocytes, which are responsible for host immune rejection. The published preclinical findings show that the arming of allogeneic T cells with an ADR selectively eliminates alloreactive T and NK cells, while sparing resting lymphocytes. Importantly, in in vivo preclinical models of cancer, allogeneic T cells expressing both an ADR and a CD19-targeted chimeric antigen receptor (CAR) demonstrated increased expansion and persistence, resulting in sustained tumor eradication and a long-term survival benefit compared to conventional CD19-targeted CAR T cells.

There is tremendous promise for the use of off-the-shelf allogeneic cells as replacement therapy. One of the most significant barriers to overcome is host immunity, which can prevent the engraftment of allogeneic cells and the long-term replacement of a patients damaged or dysfunctional cells, said Maksim Mamonkin, Ph.D., Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine and the senior author on the Nature Biotechnology publication. We are excited for Fate Therapeutics to explore the use of alloimmune defense receptors in the development of rejection-resistant, iPSC-derived cellular therapies.

About Fate Therapeutics iPSC Product Platform The Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the advancement of and plans related to the Companys NK and T-cell product candidates and preclinical research and development programs, and the scope and enforceability of the Companys intellectual property portfolio. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that results observed in preclinical studies of its product candidates may not be replicated in ongoing or future clinical trials or studies, the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that any of the patents owed or licensed by the Company may be challenged and that such a challenge may be successful, resulting in loss of any such patent or loss or reduction in the scope of one or more of the claims of a challenged patent. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com

Citius Pharmaceuticals Brings on Myron S. Czuczman, MD as Chief Medical Officer (CMO) and Executive Vice President – PRNewswire

By adminJuly 14, 2020Stell Cell Research

CRANFORD, N.J., July 14, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that Myron S. Czuczman, M.D., has joined the company as Chief Medical Officer (CMO) and Executive Vice President. Dr. Czuczman was most recently Therapeutic Area Head, Vice President, Clinical Research and Development Global Lymphoma/CLL Program at Celgene Corporation. At Celgene, he was responsible for worldwide clinical development in Lymphoma/CLL and for the development of all compounds from Proof-of-Principle through registration globally.

Myron Holubiak, Citius CEO stated, "We are honored to have a colleague as qualified as Dr. Czuczman join the Citius team. He will be enormously helpful in furthering our development program for our planned iPSC-derived mesenchymal stem cell (iMSC) for the treatment of ARDS associated with CoVid-19. This, coupled with the advanced Phase 3 trials underway for Mino-Lok and preparing an IND for Mino-Wrap, add to the importance of bringing in an executive of Dr. Czuczman's expertise, experience, and caliber to the team."

Prior to his tenure at Celgene, Dr. Czuczman served as Chief, Lymphoma/Myeloma Service in the Department of Medicine and Head of the Lymphoma Translational Research Laboratory in the Immunology Department at Roswell Park Comprehensive Cancer Center in Buffalo, NY where he attained the title of tenured Professor of Medicine and Oncology prior to joining Celgene.

Dr. Czuczman received his M.D. from Pennsylvania State University of Medicine after graduating magna cum laude in Biochemistry from the University of Pittsburgh. He completed his Internal Medicine residency training at Weill Cornell North Shore University/MSKCC Program, followed by Medical Oncology/Hematology fellowship training at Memorial Sloan-Kettering Cancer Center in New York, NY.

Dr. Czuczman was a Founding Member and reviewer forthe National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines compendium panel for nearly twenty years and he has greater than 180 peer-reviewed publications. He is a Diplomate in Internal Medicine, and is Board Certified in Medical Oncology and received numerous awards and accolades during his academic career.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Mino-LokMino-Lok is an antibiotic lock solution being developed as an adjunctive therapy in patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloodstream infections (CRBSIs). CLABSIs/CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs) and in hemodialysis patients, for whom venous access presents a challenge. There are currently no approved therapies for salvaging infected CVCs.

About Citius iMSCCitius's planned mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; the risk of successfully negotiating within the option period a license agreement with Novellus, Inc. for our planned Novecite therapy for ARDS; risks associated with conducting clinical trials and drug development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 [emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

More:
Citius Pharmaceuticals Brings on Myron S. Czuczman, MD as Chief Medical Officer (CMO) and Executive Vice President - PRNewswire

Cell Separation by Membrane Filtration Technology Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 – Cole of Duty

By adminJuly 14, 2020Stell Cell Research

Prophecy Market Insights Cell Separation by Membrane Filtration Technology market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges.

Initially, Cell Separation by Membrane Filtration Technology report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cell Separation by Membrane Filtration Technology market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/1614

As we all are well aware of pandemic and we dont know what lies ahead once this COVID-19 Pandemic crises are over. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you with an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

The executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Cell Separation by Membrane Filtration Technology market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Cell Separation by Membrane Filtration Technology research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Cell Separation by Membrane Filtration Technology market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Cell Separation by Membrane Filtration TechnologyMarket Key Players:

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/1614

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Report Scope:

Europe

Asia Pacific

Latin America

Middle East & Africa

Some Important Questions Answered in the Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Separation-by-Membrane-1614

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Go here to read the rest:
Cell Separation by Membrane Filtration Technology Market: In-depth Analysis of the Global Industry with Future Estimations till 2029 - Cole of Duty

Value and Supply Side Analysis of Key Players of Cell Therapy Manufacturing Market – Cole of Duty

By adminJuly 14, 2020Stell Cell Research

Prophecy Market Insights Cell Therapy Manufacturing market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges.

Initially, Cell Therapy Manufacturing report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cell Therapy Manufacturing market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Cell Therapy Manufacturing market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Cell Therapy Manufacturing research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Cell Therapy Manufacturing market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Cell Therapy ManufacturingMarket Key Players:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

Report Scope:

Europe

Asia Pacific

Latin America

Middle East & Africa

Some Important Questions Answered in the Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Original post:
Value and Supply Side Analysis of Key Players of Cell Therapy Manufacturing Market - Cole of Duty

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And…

By adminJuly 14, 2020Stem Cell Treatment

New Jersey, United States,- Latest update on Musculoskeletal Disorder Stem Cell Therapy Market Analysis report published with extensive market research, Musculoskeletal Disorder Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Musculoskeletal Disorder Stem Cell Therapy industry. With the classified Musculoskeletal Disorder Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Musculoskeletal Disorder Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Musculoskeletal Disorder Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Musculoskeletal Disorder Stem Cell Therapy Market growth opportunities in the industry.

Musculoskeletal Disorder Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Musculoskeletal Disorder Stem Cell Therapy market size, volume and value, as well as price data.

Musculoskeletal Disorder Stem Cell Therapy Market competition by top Manufacturers:

Musculoskeletal Disorder Stem Cell Therapy Market Classification by Types:

Musculoskeletal Disorder Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Musculoskeletal Disorder Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Musculoskeletal Disorder Stem Cell Therapy market:

Unveiling the geographical penetration of the Musculoskeletal Disorder Stem Cell Therapy market:

The report of the Musculoskeletal Disorder Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Musculoskeletal Disorder Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Musculoskeletal Disorder Stem Cell Therapy Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Pharmaxis granted orphan drug designation for PXS5505 by FDA for treatment of myelofibrosis – Proactive Investors Australia

By adminJuly 14, 2020Stem Cell Treatment

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

() has been granted an orphan drug designation for its pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis by the US Food and Drug Administration (FDA).

PXS5505 is an oral drug that inhibits all lysyl oxidase family members (LOX, LOXL1, 2, 3 & 4).

The compound successfully cleared preclinical safety including 6month toxicity studies and has shown significant reductions in fibrosis in invivo models of myelofibrosis and other cancers.

PXS5505 has shown to be well tolerated in phase 1 single and multiple ascending dose studies in humans with an excellent pharmacokinetic and pharmacodynamic profile.

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

Pharmaxis chief executive officer Gary Phillips said: We are very pleased with the FDA orphan drug designation for PXS5505.

Pharmaxis believes that the current treatments for myelofibrosis can be augmented by a panLOX inhibitor and be disease modifying in a market with high unmet need and significant deal values for programs with clinical proof of concept.

We expect to file an investigational new drug (IND) application with the FDA shortly and will provide an update on the clinical trial plans at that time.

Myelofibrosis is a rare cancer in which normal bone marrow tissue is gradually replaced with a fibrous scarlike material.

Over time, this leads to progressive bone marrow failure preventing the production of adequate numbers of red cells, white cells and platelets.

Myelofibrosis has a poor prognosis and limited therapeutic options.

Apart from a small group of patients eligible for stem cell transplantation, current standard of care are JAK1/2 inhibitors which provide mainly symptomatic relief but carry a risk of worsening blood cell counts.

A recent publication reported that Pharmaxis panLOX inhibitor compounds significantly decreased the bone marrow fibrotic burden in two different models of primary myelofibrosis.

Go here to see the original:
Pharmaxis granted orphan drug designation for PXS5505 by FDA for treatment of myelofibrosis - Proactive Investors Australia

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the…

By adminJuly 14, 2020Stell Cell Research

July 14, 2020 07:00 ET | Source: Orgenesis Inc.

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company. Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.

The companies will leverage the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform which includes point of care (POCare) Networks, POCare Therapeutics and a POCare Technologiessuite of proprietary and in-licensed technologies that have been engineered to create customized processing systems. The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network, which includes leading hospitals and research institutes around the world. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.

Vered Caplan, CEO of Orgenesis, stated, This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world. We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform. We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.

Dr Miomir Kneevi, CEO of Educell, commented, We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies. This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educells ability to ensure safety in the process and help to reduce overall manufacturing costs.

Together, the companies are working to address significant unmet market needs for producing novel cell therapies in a cost effective, high quality and scalable manner. The joint clinical development program seeks to provide safe, simplified, and cost-effective processing in an automated and controlled environment from start to finish with minimal operator intervention.

About Educell Educell Ltd, established 1997, is a company focusing on the development of cell therapy products and is a registered cell and tissue establishment. The company is preparing cell therapy products for the treatment of articular cartilage, vesicouretral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use within the University Medical Centre Ljubljana and other clinical institutions in Slovenia under the hospital exemption rule supervised by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. The companys R&D department is dedicated to the development of innovative cell therapy products and also to the development of medical devices that enable stem cell isolation and application in the operation theatre.

Educells ImmunoArt cell therapy product was developed in 2014 and is based on ex vivo expanded allogeneic mesenchymal stromal/stem cells (MSC) isolated from bone marrow. Its immunomodulatory capacity has already been proven in the clinic for the treatment of graft versus host disease (GvHD) and Chrons disease. Additional information is available at: https://www.educell.si/en/

About Orgenesis Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the Point of Care to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all. Additional information is available at: http://www.orgenesis.com.

Notice Regarding Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to effectively use the net proceeds from the sale of Masthercell, our ability to achieve and maintain overall profitability, the development of our POCare strategy, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31 2019, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis: Crescendo Communications, LLC Tel: 212-671-1021 Orgs@crescendo-ir.com

View original post here:
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis' Proprietary POCare Technologies for the...